Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Dec 08, 2017 7:05pm EST
Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting Dec 08, 2017 7:30am EST
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Nov 17, 2017 4:05pm EST
Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update Nov 07, 2017 4:01pm EST
Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results Oct 31, 2017 7:30am EDT
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares Oct 10, 2017 4:01pm EDT
